Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...
Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:RNA) with a Overweight and maintains $96 price...
Barclays analyst Gena Wang initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Overweight rating and announces Pri...
Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price t...
The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering...
Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics cal...
Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $60 price target.
